302 related articles for article (PubMed ID: 23807572)
21. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.
Yang YI; Lee KT; Park HJ; Kim TJ; Choi YS; Shih IeM; Choi JH
Carcinogenesis; 2012 Dec; 33(12):2488-98. PubMed ID: 23027625
[TBL] [Abstract][Full Text] [Related]
22. MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88.
Zhan Y; Xiang F; Wu R; Xu J; Ni Z; Jiang J; Kang X
J Ovarian Res; 2015 Jul; 8():48. PubMed ID: 26223974
[TBL] [Abstract][Full Text] [Related]
23. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
24. Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer.
Wei L; Xue T; Wang J; Chen B; Lei Y; Huang Y; Wang H; Xin X
Int J Cancer; 2009 Aug; 125(4):791-806. PubMed ID: 19391138
[TBL] [Abstract][Full Text] [Related]
25. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.
Kim SH; Juhnn YS; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():82-9. PubMed ID: 17404021
[TBL] [Abstract][Full Text] [Related]
26. Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells.
Isonishi S; Saitou M; Saitou M; Yasuda M; Tanaka T
Oncol Rep; 2007 Jul; 18(1):195-201. PubMed ID: 17549368
[TBL] [Abstract][Full Text] [Related]
27. Synergistic effects of PectaSol-C modified citrus pectin an inhibitor of Galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells.
Hossein G; Keshavarz M; Ahmadi S; Naderi N
Asian Pac J Cancer Prev; 2013; 14(12):7561-8. PubMed ID: 24460334
[TBL] [Abstract][Full Text] [Related]
28. [Impact of cyclin-dependent kinase inhibitor p27 on resistance of ovarian cancer multicellular spheroids to taxol].
Xing H; Li J; Gao QL; Wu JH; Gao C; Lu YP; Ma D
Zhonghua Yi Xue Za Zhi; 2003 Jan; 83(1):37-41. PubMed ID: 12757643
[TBL] [Abstract][Full Text] [Related]
29. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.
Mitsuuchi Y; Johnson SW; Selvakumaran M; Williams SJ; Hamilton TC; Testa JR
Cancer Res; 2000 Oct; 60(19):5390-4. PubMed ID: 11034077
[TBL] [Abstract][Full Text] [Related]
30. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
Faria RS; de Lima LI; Bonadio RS; Longo JPF; Roque MC; de Matos Neto JN; Moya SE; de Oliveira MC; Azevedo RB
Biomed Pharmacother; 2021 Oct; 142():112000. PubMed ID: 34426249
[TBL] [Abstract][Full Text] [Related]
31. Silibinin restores paclitaxel sensitivity to paclitaxel-resistant human ovarian carcinoma cells.
Zhou L; Liu P; Chen B; Wang Y; Wang X; Chiriva Internati M; Wachtel MS; Frezza EE
Anticancer Res; 2008; 28(2A):1119-27. PubMed ID: 18507063
[TBL] [Abstract][Full Text] [Related]
32. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
[TBL] [Abstract][Full Text] [Related]
33. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
[TBL] [Abstract][Full Text] [Related]
34. Knockdown of cyclophilin A reverses paclitaxel resistance in human endometrial cancer cells via suppression of MAPK kinase pathways.
Li Z; Min W; Gou J
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1001-11. PubMed ID: 24036847
[TBL] [Abstract][Full Text] [Related]
35. HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor.
Pavan S; Musiani D; Torchiaro E; Migliardi G; Gai M; Di Cunto F; Erriquez J; Olivero M; Di Renzo MF
Int J Cancer; 2014 Mar; 134(6):1289-99. PubMed ID: 23996744
[TBL] [Abstract][Full Text] [Related]
36. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
Xu Y; Zhang J; Wu J; Zhong S; Li H
Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
[TBL] [Abstract][Full Text] [Related]
38. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
[TBL] [Abstract][Full Text] [Related]
39. Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis.
Xue YN; Yu BB; Liu YN; Guo R; Li JL; Zhang LC; Su J; Sun LK; Li Y
Prostate; 2019 May; 79(6):647-656. PubMed ID: 30714183
[TBL] [Abstract][Full Text] [Related]
40. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
